Life Sciences Investment Programme

The Life Sciences Investment Programme (LSIP) is a £200m initiative managed by British Patient Capital designed to address the growth equity finance gap faced by high-potential UK life sciences companies. This is expected to attract at least a further £400m of private investment.

Through LSIP, we make cornerstone commitments to later stage life sciences venture growth funds with a strong UK focus, typically investing between £50m and £100m in each successful fund.

Key features

• Dedicated life sciences focus
• Funds providing later-stage capital
• UK presence in investment team
• Minimum target fund size of £250m
• Focus on funding UK companies